Skip to content Skip to footer

PBI-Gordon Companies Acquires TriviumVet, Expanding its Animal Healthcare Product Portfolio

Shots:

  • PBI-Gordon Companies has acquired TriviumVet, incl. its product Felycin-CA1 (Sirolimus Delayed-Release Tablets), adding it to the PRN Pharmacal portfolio (PBI-Gordon’s Brand) to expand its animal healthcare product portfolio
  • Felycin-CA1 will be available for veterinary orders by Aug 2025, with PRN Pharmacal expanding its team by hiring over 50 additional employees
  • Felycin-CA1 has been conditionally approved by the US FDA for managing ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM)

Ref: PRNewswire | Image: TriviumVet

Related News:- Virbac Launches Zenifel Pheromone Product to Address Stress-Related Behaviors in Cats

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click Here for Full Press Release

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]